Rezolute, Inc. Announces Closing of Underwritten Offering

Rhea-AI Summary

Rezolute (NASDAQ: RZLT) has successfully closed its previously announced underwritten offering, raising approximately $96.9 million in net proceeds. The offering included 24,940,769 shares of common stock at $3.25 per share, including 4,153,846 shares from the underwriters' option, and pre-funded warrants for 6,905,385 shares at $3.2490 per warrant.

The offering attracted notable investors including Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, and Great Point Partners. Additionally, existing investors have committed to purchase up to $4.2 million in shares through a separate private placement expected to close around May 7, 2025.

Guggenheim Securities served as the sole book-running manager, with BTIG, H.C. Wainwright & Co., and Jones as lead managers. The company plans to use the proceeds for research and development, general corporate expenses, and working capital needs.

Positive

• Substantial capital raise of $96.9M through public offering
• Additional $4.2M committed through private placement
• Strong institutional investor participation including major firms
• Full exercise of underwriters' option indicating strong demand

Negative

• Significant dilution for existing shareholders due to large share issuance
• Warrant issuance could lead to additional future dilution

Insights

Financial Analyst

Rezolute's $96.9M capital raise strengthens balance sheet substantially, despite significant dilution at below-market pricing of $3.25/share.

Rezolute has successfully closed a $96.9 million underwritten offering consisting of 24,940,769 shares of common stock priced at $3.25 per share and pre-funded warrants. This represents a substantial capital infusion for a company with a market cap of approximately $166 million, effectively securing funding that's equivalent to 58% of their pre-offering valuation.

The pricing at $3.25 represents a 15.6% discount to the current share price of $3.85, which is within typical range for biotech secondary offerings. What's particularly noteworthy is the impressive roster of institutional investors participating, including Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, and several specialized healthcare funds like Great Point Partners and Woodline Partners.

Beyond the main offering, the company has secured commitments for an additional $4.2 million in a separate private placement expected to close around May 7th. This transaction structure – combining a public offering with a follow-on private placement – suggests a strategic approach to capital raising while managing market impact.

While this financing substantially improves Rezolute's cash position and extends their operational runway, it comes with significant dilution for existing shareholders. However, for a clinical-stage biotech company with promising late-stage assets in rare diseases, securing this level of financial backing represents a vote of confidence from sophisticated institutional investors and provides the necessary capital to advance their pipeline through critical development milestones.

Biotech Investment Specialist

Nearly $100M raise gives Rezolute substantial runway to advance ersodetug through final development stages for rare hypoglycemia conditions.

This $96.9 million capital infusion transforms Rezolute's ability to advance their lead asset ersodetug, an antibody therapy targeting hypoglycemia caused by hyperinsulinism (HI). As specified in the article, ersodetug is designed to treat all forms of HI and has already demonstrated "substantial benefit in clinical trials and real-world use" for both congenital HI and tumor HI – rare but serious conditions with treatment options.

The company explicitly states they'll use proceeds for "research and development, general corporate expenses and working capital needs," giving them flexibility to allocate capital efficiently across their development programs. For a rare disease-focused company in late clinical stages, this funding level is particularly meaningful as it potentially provides sufficient capital to complete pivotal studies and prepare for commercial activities.

Most revealing is the caliber of investors participating in this round. The presence of specialized healthcare investors like Great Point Partners and Woodline Partners, alongside major institutions like Blackstone and Federated Hermes, signals strong conviction in Rezolute's clinical data and regulatory prospects. These sophisticated investors typically conduct extensive due diligence on clinical data, regulatory pathways, and market potential before committing capital at this scale.

For a company developing treatments for rare diseases like hyperinsulinism, which affects roughly 1 in 25,000 to 50,000 newborns, securing nearly $100 million provides the financial stability needed to execute their clinical development strategy without compromising on study design or implementation due to capital constraints.

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its previously announced underwritten offering (the “Offering”) of an aggregate of 24,940,769 shares of its common stock at an offering price of $3.25 per share, which includes 4,153,846 shares of common stock pursuant to the exercise in full of the underwriters’ option to purchase additional shares of common stock and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 6,905,385 shares of common stock at an offering price of $3.2490 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant.

Net proceeds from the Offering are expected to be approximately $96.9 million. The Company intends to use the net proceeds from the Offering for research and development, general corporate expenses and working capital needs.

The Offering included participation from new and existing investors, including Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, Great Point Partners, LLC, Marshall Wace, Woodline Partners LP, Nantahala Capital, Squadron Capital Management and select mutual funds.

Guggenheim Securities acted as the sole book-running manager for the Offering. BTIG, H.C. Wainwright & Co., and Jones acted as lead managers for the Offering. Craig-Hallum and Maxim Group LLC acted as co-managers for the Offering. WG Partners LLP acted as financial advisor for the Offering.

In addition to the Offering, certain existing investors have committed to purchase up to an additional $4.2 million shares of common stock in a private placement at the same offering price in a separate private placement (the “Private Placement”). The Private Placement is expected to close on or about May 7, 2025, subject to satisfaction of customary closing conditions.

A shelf registration statement on Form S-3 (File No. 333-275562) relating to the securities offered in the Offering was filed with the Securities and Exchange Commission (the “SEC”) and was declared effective on November 29, 2023. The Offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A final prospectus supplement and the accompanying prospectus relating to and describing the terms of the Offering was filed with the SEC and may be obtained on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the Offering, may be obtained by contacting: Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (“HI”). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI.

Forward-Looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including statements regarding the Private Placement and statements regarding the Company’s expectations on the use of proceeds from the Offering, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to market and other financial conditions, the completion of the Private Placement or the size or terms thereof, satisfaction of customary closing conditions related to the Private Placement and other factors discussed in the “Risk Factors” section contained in the final prospectus supplement that have been filed with the SEC and other reports that the Company has filed with the SEC. Any forward-looking statements represent the Company’s views only as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.

Contacts:

Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Media
Sarah Lima
Sarah@GalvinPR.com
(774) 766-0200

FAQ

How much did Rezolute (RZLT) raise in their latest offering?

Rezolute raised approximately $96.9 million in net proceeds through their underwritten offering, with an additional $4.2 million expected from a private placement.

What was the share price for RZLT's April 2025 offering?

The offering price was $3.25 per share of common stock, and $3.2490 for pre-funded warrants.

Who were the major investors in Rezolute's 2025 offering?

Major investors included Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, Great Point Partners, Marshall Wace, Woodline Partners LP, and Nantahala Capital.

How will RZLT use the proceeds from their 2025 offering?

Rezolute plans to use the net proceeds for research and development, general corporate expenses, and working capital needs.